WE CLAIM:

1. A compound represented by the general formula (I):



(I)

wherein A_1 is an alkyl amino acid residue selected from Cha, Leu and Ile, an amino alkyl amino acid residue selected from Arg and Lys, or an aryl amino acid residue selected from Phe, substituted Phe, Tyr, or Trp;

A_2 is an amino alkyl amino acid residue selected from Lys, Orn, Arg, and homo Arg;

A_3 is an aryl amino acid residue selected from Phe, substituted Phe, homo Phe, Tyr, Trp, phgly, 2-Thala and 3-Thala, an alkyl amino acid residue selected from Cha, Leu and Ile, an amido alkyl amino acid selected from Asn and Gln, or an amino alkyl amino acid residue selected from Arg, homo Arg, Orn and Lys;

X is selected from CO, CS, or SO_2;

Y is selected from aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylethylenyl, substituted heteroarylethylenyl, arylacrylamidoheteroaryl, substituted arylacrylamidoheteroaryl, heteroarylacrylamidoheteroaryl and substituted heteroarylacrylamidoheteroaryl, provided that Y is not pyrrolidinyl, phenyl or 2-aminophenyl;

Z is selected from NH_2, NH-alkyl, NH-aralkyl, or an amino alkyl amino acid residue selected from Arg-NH_2; and

wherein all amino acids are of the L configuration;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1, wherein

A_3 is an aryl amino acid residue selected from Phe, substituted Phe, Tyr, Trp, phgly, 2-Thala and 3-Thala, an alkyl amino acid residue selected from Cha, Leu and Ile, an amido alkyl amino acid selected from Asn and Gln, or an amino alkyl amino acid residue selected from Arg, homo Arg, Orn and Lys; and

Y is selected from heteroaryl, substituted heteroaryl, arylacrylamidoheteroaryl, and substituted arylacrylamidoheteroaryl;

and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2, wherein

A_1 is an alkyl amino acid residue selected from Cha, Leu and Ile, or an aryl amino acid residue selected from Phe, substituted Phe, Tyr, or Trp;

A_2 is an amino alkyl amino acid residue selected from Lys or Arg;

A_3 is an aryl amino acid residue selected from Phe, substituted Phe, Tyr, Trp, Phgly and 2-Thala;

X is selected from CO or SO_2;
and pharmaceutically acceptable salts thereof.

4. The compound of Claim 3, wherein

X is CO;

Y is selected from benzothiophenyl, substituted benzothiophenyl, pyridinyl, substituted pyridinyl, triazolyl, substituted triazolyl, chromonyl, quinoxalinyl, thiadiazolyl, substituted thiadiazolyl, pyrazinyl, substituted pyrazinyl, pyridylethylenyl, substituted pyridylethylenyl, cinnamamido-triazolyl, substituted cinnamamido-triazolyl, thiophenylacrylamido-triazolyl, or naphthylacrylamido-triazolyl;

Z is selected from NH_2 or Arg-NH_2;

and pharmaceutically acceptable salts thereof.

5. The compound of Claim 4, wherein

A_1 is selected from Cha or Phe;

A_2 is selected from Arg or Lys;

A_3 is selected from Phe;

and pharmaceutically acceptable salts thereof.

6. The compound of Claim 5, selected from:

(5-Bromopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

2-Chromonylcarbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(5-Aminotriazol-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[5-(χ-Methyl)cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

{5-[3-(1-Naphthyl)acrylamido]triazol-3-yl}carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[Quinoxalin-2-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[5-(o-Chlorocinnamamido)triazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Aminopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(5-Aminotriazol-3-yl)carbonyl-phenylalanyl-arginyl-phenylalanyl-arginineamide;

(5-Aminotriazol-3-yl)carbonyl-cyclohexylalanyl-lysinyl-phenylalanineamide;

{5-[3-(2-Thienyl)acrylamido]triazol-3-yl}carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[5-cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Cinnamamidopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide; or

(5-Chloro-3-methyl-benzothiophen-2-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

and pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

8. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

9. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

10. A method of treating a condition mediated by modulation of the thrombin receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.

11. The method of Claim 10, wherein the condition is selected from wound healing, tissue repair, myocardial infarction, stroke, restenosis, angina, atherosclerosis, ischemic attacks, inflammation, cancer, osteoporosis, or neurodegenerative disorders.

12. The method of Claim 11, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

13. The method of Claim 12, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.

14. A method of treating a condition modulated by the thrombin receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 7.

15. The method of Claim 14, wherein the condition is selected from wound healing, tissue repair, myocardial infarction, stroke, restenosis, angina, atherosclerosis, ischemic attacks, inflammation, cancer, osteoporosis, or neurodegenerative disorders.

16. The method of Claim 14, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

17. The method of Claim 16, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.